UK begins trials of Ebola vaccine developed in just eight weeks
UK Launches Trials for Rapidly Developed Ebola Vaccine
UK begins trials of Ebola vaccine - The United Kingdom has cleared the way for human trials of an experimental Ebola vaccine, which was created in just eight weeks. This marks a significant milestone in the fight against the ongoing outbreak in the Democratic Republic of the Congo (DRC), where 625 lives have been lost and 1,792 cases confirmed. The vaccine, developed by researchers at the University of Oxford, is the first of four candidates to progress to clinical testing.
Accelerated Development Amid Public Health Crisis
Work on the vaccine began on 17 May when a public health emergency was declared. Scientists leveraged the same technology used in the Oxford/AstraZeneca Covid vaccine, which gained global recognition during the pandemic. This approach allowed them to fast-track the development process without compromising on rigorous testing procedures.
The vaccine employs a modified chimpanzee common cold virus as a delivery system. Instead of the entire virus, researchers replace a specific genetic segment with one from the Bundibugyo strain of Ebola. This snippet instructs the body to produce a single viral protein, prompting the immune system to respond as if exposed to the real virus.
"We're conducting phase one trials of new vaccines routinely, specifically to prepare for outbreaks like this," said Dr. Katrina Pollock, lead investigator at the University of Oxford. The trial will involve 50 healthy adults aged 18 to 55, with monitoring lasting up to a year.
The Oxford team has produced and stored approximately 620,000 doses of the vaccine, which has already been tested on mice and macaque monkeys. The Serum Institute of India is manufacturing it to meet clinical standards. The UK's Medicines and Healthcare Products Regulatory Agency approved the trials based on this data, ensuring safety protocols are in place.
Risk Assessment and Trial Considerations
Dr. Pollock emphasized that severe side effects are expected to be rare, and the team carefully evaluated the risks for volunteers. "I want to stress that the AstraZeneca vaccine was given safely to millions," she noted, highlighting the cautious approach despite the expedited timeline.
Vaccine development typically spans a decade, but the urgency of the outbreak enabled rapid scaling. Alex Sampson, a researcher involved in the project, told the BBC: "As soon as we heard of the outbreak, we could accelerate production significantly." While the new vaccine may share some risks with the Oxford/AstraZeneca Covid vaccine—such as rare blood clots—these are considered less severe than the threat posed by the Bundibugyo strain, which kills about a third of its victims.
The outbreak, occurring in a conflict zone with highly mobile populations, underscores the critical need for a swift response. Researchers are also collaborating with Ugandan partners to prepare for trials in Africa, aiming to address the epidemic's challenges effectively.